Vascular-targeted cancer gene therapy

Bibliography

• ROCHLITZ CF: Gene therapy of cancer. Swiss Med. Wkly (2001) 131:4–9.
   PubMed Web of Science ®Google Scholar
• SMILEY WR, LAUBERT B,HOWARD BD et al.: Establishment ofparameters for optimal transduction efficiency and antitumor effects with purified high-titer HSV-TK retroviral vector in established solid tumors. Hum. Gene The]: (1997) 8:965–977.
   Google Scholar
• RAINOV NG, KRAMM CM: Vector delivery methods and targeting strategies for gene therapy of brain tumors. Curl: Gene Thec (2001) 1:367–383.
   PubMedGoogle Scholar
• BILBAO R, BUSTOS M,ALZUGUREN P et al: A blood-tumorbarrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds. Gene Thec (2000) 7:1824–1832.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev (1990) 9:253–266.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Tumor angiogenesis. Adv. Cancer Res. (1985) 43:175–203.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. (2002) 29:15–18.
   PubMed Web of Science ®Google Scholar
• DENEKAMP J: Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev (1990) 9:267–282.
   PubMed Web of Science ®Google Scholar
• ••A first-rate review by an early proponentand passionate advocate of the approach, describing the rationale and merits of targeting tumour vasculature.
   Google Scholar
• RANIERI G, GASPARINI G: Angiogenesis and angiogenesis inhibitors: a new potential anticancer therapeutic strategy. Curr. Drug Targets Immune Endocr. Metabol. Disord. (2001) 1:241–253.
   PubMedGoogle Scholar
• NICHOLSON B, SCHAEFER G, THEODORESCU D: Angiogenesis in prostate cancer: biology and therapeutic opportunities. Cancer Metastasis Rev (2001) 20:297–319.
   PubMed Web of Science ®Google Scholar
• SIM BK, MACDONALD NJ,GUBISH ER: Angiostatin and endostatin: endogenous inhibitors of tumor growth. Cancer Metastasis Rev (2000) 19:181–190.
   PubMed Web of Science ®Google Scholar
• KERBEL RS: Antiangiogenic drugs and current strategies for the treatment of lung cancer. Semin. Oncol. (2004) 31:54–60.
   PubMed Web of Science ®Google Scholar
• DENEKAMP J, DASU A, WAITES A: Vasculature and microenvironmental gradients: the missing links in novel approaches to cancer therapy. Adv. Enzyme Regal. (1998) 38:281–299.
   PubMedGoogle Scholar
• CHAPLIN DJ, HILL SA: Selective induction of tumor ischemia: development of vascular targeting agents for cancer therapy. Curt: Opin. Investig. Drugs (2002) 3:1381–1384.
   PubMedGoogle Scholar
• DAVIS PD, DOUGHERTY GJ, BLAKEY DC et al.: ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res. (2002) 62:7247–7253.
   PubMed Web of Science ®Google Scholar
• THORPE PE, CHAPLIN DJ,BLAKEY DC: The first international conference on vascular targeting: meeting overview. Cancer Res. (2003) 63:1144–1147.
   PubMedGoogle Scholar
• SIEMANN DW, CHAPLIN DJ, HORSMAN MR: Vascular-targeting therapies for treatment of malignant disease. Cancer (2004) 100:2491–2499.
   PubMed Web of Science ®Google Scholar
• •Timely review focusing on small molecule vascular-targeting agents, describing recent progress and clinical experience.
   Google Scholar
• THORPE PE: Vascular targeting agents ascancer therapeutics. Clin. Cancer Res. (2004) 10:415–427.
   PubMed Web of Science ®Google Scholar
• SMITH L, BYERS JF: Gene therapy in the post-Gelsinger era. JONAS Healthc. Law Ethics Regul. (2002) 4:104–110.
   PubMedGoogle Scholar
• RUBANYI GM: The future of human gene therapy. Mol. Aspects Med. (2001) 22:113–142.
   PubMedGoogle Scholar
• WILLIAMS DA, BAUM C: Medicine. Gene therapy-new challenges ahead. Science (2003) 302:400–401.
   Google Scholar
• KAISER J: Gene therapy. Seeking the cause of induced leukemias in X-SCID trial. Science (2003) 299:495.
   Google Scholar
• KOHN DB, SADELAIN M,GLORIOSO JC: Occurrence of leukaemia following gene therapy of X-linked SCID. Nat. Rev Cancer (2003) 3:477–488.
   PubMed Web of Science ®Google Scholar
• MCCORMACK MP, FORSTER A, DRYNAN L, PANNELL R,RABBITTS TH: The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development. Mel Cell Biol. (2003) 23:9003–9013.
   Web of Science ®Google Scholar
• FOX JL: US authorities uphold suspension of SCID gene therapy. Nat. Biotechnol. (2003) 21:217.
   PubMed Web of Science ®Google Scholar
• CHAPLIN DJ, DOUGHERTY GJ: Tumour vasculature as a target for cancer therapy. Br. Cancer (1999) 80\(Suppl. 1):57–64.
   Google Scholar
• YANG ZY, DUCKERS HJ,SULLIVAN NJ, SANCHEZ A,NABEL EG, NABEL GJ: Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med. (2000) 6:886–889.
   PubMed Web of Science ®Google Scholar
• DROPULIC B, MASTERS CL: Entry of neurotropic arboviruses into the central nervous system: an M vitro study using mouse brain endothelium. I Infect. Dis. (1990) 161:685–691.
   PubMed Web of Science ®Google Scholar
• GERNA G, BALDANTI F,REVELLO MG: Pathogenesis of human cytomegalovirus infection and cellular targets. Hum. Immunol. (2004) 65:381–386.
   PubMed Web of Science ®Google Scholar
• AGNELLO V, ABEL G: Localization of hepatitis C virus in cutaneous vasculitic lesions in patients with type II cryoglobulinemia. Arthritic Rheum. (1997) 40:2007–2015.
   PubMed Web of Science ®Google Scholar
• CHI D, HENRY J, KELLEY J,THORPE R, SMITH JK,KRISHNASWAMY G: The effects of HIV infection on endothelial function. Endothelium (2000) 7:223–242.
   PubMed Web of Science ®Google Scholar
• TOMKO RP, XU R, PHILIPSON L: HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Nati Acad. Sci. USA (1997) 94:3352–3356.
   PubMed Web of Science ®Google Scholar
• BERGELSON JM, CUNNINGHAM JA, DROGUETT G et al.: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (1997) 275:1320–1323.
   PubMed Web of Science ®Google Scholar
• ••Identification and initial characterisationof CAR, the broadly distributed cell surface molecule that functions as a receptor for adenoviral vectors.
   Google Scholar
• WICKHAM TJ, MATHIAS P,CHERESH DA, NEMEROW GR: Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell (1993) 73:309–319.
   PubMed Web of Science ®Google Scholar
• ••Description of the two-step model inwhich integrins play an essential role in the uptake of adenoviral particles after initial binding to CAR.
   Google Scholar
• GREBER UF, WILLETTS M,WEBSTER P, HELENIUS A: Stepwise dismantling of adenovirus 2 during entry into cells. Cell (1993) 75:477–486.
   PubMed Web of Science ®Google Scholar
• WANG K, HUANG S,KAPOOR-MUNSHI A, NEMEROW G: Adenovirus internalization and infection require dynamin. Viral. (1998) 72:3455–3458.
   PubMed Web of Science ®Google Scholar
• BERGELSON JM: Receptors mediating adenovirus attachment and internalization. Biechein. Phannacel (1999) 57:975–979.
   PubMed Web of Science ®Google Scholar
• MICHAEL SI, HONG JS, CURIEL DT, ENGLER JA: Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther. (1995) 2:660–668.
   PubMed Web of Science ®Google Scholar
• PEARSON AS, KOCH PE,ATKINSON N et al.: Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines. Clin. Cancer Res. (1999) 5:4208–4213.
   Google Scholar
• BILBAO G, GOMEZ-NAVARRO J, CURIEL DT: Targeted adenoviral vectors for cancer gene therapy. Adv. Exp. Med. Biel. (1998) 451:365-374.Curiel and colleagues have played a leading role in the development of targetable adenoviral vectors, and this review details both their experience and the challenges associated with this approach.
   Google Scholar
• KRASNYKH V, DMITRIEV I,NAVARRO JG et al.: Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity. Cancer Res. (2000) 60:6784–6787.
   Google Scholar
• WICKHAM TJ, LEE GM, TITUS JA et al.: Targeted adenovirus-mediated gene delivery to T cells via CD3. Virol. (1997) 71:7663–7669.
   Web of Science ®Google Scholar
• •Formal demonstration that a single cell surface protein (in this case CD3) can substitute for both CAR and integrins to permit the infection of target cells by genetically engineered adenoviral vectors.
   Google Scholar
• ADAMS MD, KERLAVAGE AR, FLEISCHMANN RD et al.: Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence. Nature (1995) 377:3–174.
   PubMed Web of Science ®Google Scholar
• DENEKAMP J: Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. ELI Radio]. (1993) 66:181–196.
   Google Scholar
• ZHANG HT, GORN M, SMITH K, GRAHAM AP, LAU KK, BICKNELL R: Transcriptional profiling of human microvascular endothelial cells in the proliferative and quiescent state using cDNA arrays. Angiogenesis (1999) 3:211–219.
   PubMedGoogle Scholar
• SENGER DR, CLAFFEY KP, BENES JE, PERRUZZI CA, SERGIOU AP, DETMAR M: Angiogenesis promoted by vascular endothelial growth factor: regulation through alphalbeta1 and alpha2betal integrins. Proc. Natl. Acad. Sci. USA (1997) 94:13612–13617.
   PubMed Web of Science ®Google Scholar
• FABBRI M, CASTELLANI P, GOTWALS PJ, KOTELIANSKI V, ZARDI L, ZOCCHI MR: A functional monoclonal antibody recognizing the human alpha 1-integrin I-domain. Tissue Antigens (1996) 48:47–51.
   PubMed Web of Science ®Google Scholar
• ENENSTEIN J, KRAMER RH: Confocal microscopic analysis of integrin expression on the microvasculature and its sprouts in the neonatal foreskin. Invest. Dennatol. (1994) 103:381–386.
   PubMed Web of Science ®Google Scholar
• DEFILIPPI P, VAN HINSBERGH V, BERTOLOTTO A, ROSSINO P, SILENGO L, TARONE G: Differential distribution and modulation of expression of alpha 1/beta 1 integrin on humanendothelial cells. Cell Biol. (1991) 114:855–863.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, MONTGOMERY AM, ROSENFELD M et al.: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 79:1157–1164.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, STROMBLAD S, KLEMKE R, VISSCHER D, SARKAR FH, CHERESH DA: Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. j. Clin. Invest. (1995) 96:1815–1822.
   PubMed Web of Science ®Google Scholar
• KOZIAN DH, AUGUSTIN HG: Rapid identification of differentially expressed endothelial cell genes by RNA display. Biochem. Biophys. Res. Commun. (1995) 209:1068–1075.
   PubMed Web of Science ®Google Scholar
• PROLS F, LOSER B, MARX M: Differential expression of osteopontin, PC4, and CEC5, a novel mRNA species, during M vitro angiogenesis. Exp. Cell Res. (1998) 239:1–10.
   PubMed Web of Science ®Google Scholar
• KRASNYKH V, DMITRIEV I, MIKHEEVA G, MILLER CR, BELOUSOVA N, CURIEL DT: Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. Vim/. (1998) 72:1844–1852.
   Web of Science ®Google Scholar
• NICKLIN SA, WHITE SJ, NICOL CG, VON SEGGERN DJ, BAKER AH: In vitro and in vivo characterisation of endothelial cell selective adenoviral vectors. J. Gene Med. (2004) 6:300–308.
   PubMed Web of Science ®Google Scholar
• •One of several recent papers in which phage display techniques were used to isolate defined peptides that were then incorporated into the adenoviral fibre protein in order to produce vectors that preferentially target endothelial cells.
   Google Scholar
• MULLER 0J, KAUL F, WEITZMAN MD et al: Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat. Biotechnol. (2003) 21:1040–1046.
   PubMed Web of Science ®Google Scholar
• WHITE SJ, NICKLIN SA, BUNING H et al: Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation (2004) 109:513–519.
   PubMed Web of Science ®Google Scholar
• LIU L, ANDERSON WE BEART RW, GORDON EM, HALL FL: Incorporation of tumor vasculature targeting motifs into moloney murine leukemia virus env escort proteins enhances retrovirus binding andtransduction of human endothelial cells. .1. Virol. (2000) 74:5320–5328.
   Google Scholar
• MASOOD R, GORDON EM, WHITLEY MD et al.: Retroviral vectors bearing IgG-binding motifs for antibody-mediated targeting of vascular endothelial growth factor receptors. Int. J. Mol. Med. (2001) 8:335–343.
   PubMed Web of Science ®Google Scholar
• DOUGHERTY GJ, PETERS CE, DOUGHERTY ST, MCBRIDE WH, CHAPLIN DJ: Development of targetable retroviral vectors. Transfus. Sci. (1996) 17:121–128.
   Google Scholar
• GRAULICH W, NETTELBECK DM, FISCHER D, KISSEL T, MULLER R: Cell type specificity of the human endoglin promoter. Gene (1999) 227:55–62.
   PubMed Web of Science ®Google Scholar
• NICKLIN SA, REYNOLDS PN, BROSNAN MJ et al.: Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension (2001) 38:65–70.
   PubMed Web of Science ®Google Scholar
• REYNOLDS PN, NICKLIN SA, KALIBEROVA L et al.: Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat. Biotechnol. (2001) 19:838–842.
   PubMed Web of Science ®Google Scholar
• KORHONEN J, LAHTINEN I, HALMEKYTO M et al.: Endothelial-specific gene expression directed by the tie gene promoter in vivo. Blood (1995) 86:1828–1835.
   PubMed Web of Science ®Google Scholar
• DE PALMA M, VENNERI MA, NALDINI L: In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum. Gene Ther. (2003) 14:1193–1206.
   PubMed Web of Science ®Google Scholar
• COWAN PJ, SHINKEL TA, WITORT EJ, BARLOW H, PEARSE MJ, D'APICE AJ: Targeting gene expression to endothelial cells in transgenic mice using the human intercellular adhesion molecule 2 promoter. Transplantation (1996) 62:155–160.
   PubMed Web of Science ®Google Scholar
• VELASCO B, RAMIREZ JR,RELLOSO M et al.: Vascular gene transfer driven by endoglin and ICAM-2 endothelial-specific promoters. Gene Ther. (2001) 8:897–904.
   Google Scholar
• RICHARDSON TB, KASPERS J, PORTER CD: Retroviral hybrid LTR vector strategy: functional analysis of LTR elements and generation of endothelial cell specificity. Gene Ther. (2004) 11:775–783.
   PubMed Web of Science ®Google Scholar
• DANCER A, JULIEN S, BOUILLOT S, POINTU H, VERNET M, HUBER P: Expression of thymidine kinase driven by an endothelial-specific promoter inhibits tumor growth of Lewis lung carcinoma cells in transgenic mice. Gene Ther. (2003) 10:1170–1178.
   PubMed Web of Science ®Google Scholar
• JAGER U, ZHAO Y, PORTER CD: Endothelial cell-specific transcriptional targeting from a hybrid long terminal repeat retrovirus vector containing human prepro-endothelin-1 promoter sequences. J. Vim/. (1999) 73:9702–9709.
   Web of Science ®Google Scholar
• MAVRIA G, JAGER U, PORTER CD: Generation of a high titre retroviral vector for endothelial cell-specific gene expression in vivo. Gene Ther. (2000) 7:368–376.
   PubMed Web of Science ®Google Scholar
• VARDA-BLOOM N, SHAISH A, GONEN A et al.: Tissue-specific gene therapy directed to tumor angiogenesis. Gene The]: (2001) 8:819–827.
   PubMed Web of Science ®Google Scholar
• CHO J, LIM W, JANG S, LEE Y: Development of an efficient endothelial cell specific vector using promoter and 5' untranslated sequences from the human preproendothelin-1 gene. Exp. Ma Med. (2003) 35:269–274.
   PubMed Web of Science ®Google Scholar
• GREENBERGER S, SHAISH A, VARDA-BLOOM N et al: Transcription-controlled gene therapy against tumor angiogenesis. Clin. Invest. (2004) 113:1017–1024.
   Google Scholar
• SAVONTAUS MJ, SAUTER BV, HUANG TG, WOO SL: Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells. Gene The]: (2002) 9:972–979.
   PubMed Web of Science ®Google Scholar
• DAI C, MCANINCH RE, SUTTON RE: Identification of synthetic endothelial cell-specific promoters by use of a high-throughput screen. Virol (2004) 78:6209–6221.
   Web of Science ®Google Scholar
• ••A promising study describing a noveltechnique that can be used to derive synthetic promoter elements that exhibit high activity and specificity for particular cell types.
   Google Scholar
• EDELMAN GM, MEECH R,OWENS GC, JONES FS: Synthetic promoter elements obtained by nucleotide sequence variation and selection for activity. Proc. Nati Acad. Sci. USA (2000) 97:3038–3043.
   PubMed Web of Science ®Google Scholar
• ••Isolation of synthetic muscle-specificpromoter elements that exhibit activity greater than that of commonly used naturally occurring sequences.
   Google Scholar
• LI X, EASTMAN EM, SCHWARTZ RJ, DRAGHIA-AKLI R: Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat. Biotechnol (1999) 17:241–245.
   PubMed Web of Science ®Google Scholar
• WORTHINGTON J, ROBSON T, MURRAY M, O'ROURKE M, KEILTY G, HIRST DG: Modification of vascular tone using iNOS under the control of a radiation-inducible promoter. Gene Ther. (2000) 7:1126–1131.
   PubMed Web of Science ®Google Scholar
• GRECO O, MARPLES B, DACHS GU, WILLIAMS KJ, PATTERSON AV, SCOTT SD: Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Tiler: (2002) 9:1403–1411.
   Web of Science ®Google Scholar
• KUFE D, WEICHSELBAUM R: Radiation therapy: activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology. Cancer Biol. Ther. (2003) 2:326–329.
   PubMed Web of Science ®Google Scholar
• CARPENITO C, DAVIS PD,DOUGHERTY ST, DOUGHERTY GJ: Exploiting the differential production of angiogenic factors within the tumor microenvironment in the design of a novel vascular-targeted gene therapy-based approach to the treatment of cancer. Int. .1. Radiat. Oncol Biol. Phys. (2002) 54:1473–1478.
   Google Scholar
• •Description of a novel, functional targeting strategy that exploits the differential production of VEGF within the tumour microenvironment in order to selectively kill tumour-associated vascular endothelial cells.
   Google Scholar
• ACKER T, PLATE KH: Hypoxia and hypoxia inducible factors (HIE) as important regulators of tumor physiology. Cancer Treat. Res. (2004) 117:219–248.
   PubMedGoogle Scholar
• CROSS MJ, DIXELIUS J, MATSUMOTO T,CLAESSON-WELSH L: VEGF-receptor signal transduction. Trends Biochem. Sci. (2003) 28:488–494.
   PubMed Web of Science ®Google Scholar
• HAYES GM, CARPENITO C,DAVIS PD, DOUGHERTY ST,DIRKS JF, DOUGHERTY GJ: Alternative splicing as a novel of means of regulating the expression of therapeutic genes. Cancer Gene Ther. (2002) 9:133–141.
   PubMed Web of Science ®Google Scholar
• •Demonstration of the use of differential alternative splicing as a means of targeting gene expression to particular cell types.
   Google Scholar
• GRIFFIOEN AW, COENEN MJ, DAMEN CA et al.: CD44 is involved in tumor angiogenesis; an activation antigen on human endothelial cells. Blood (1997) 90:1150–1159.
   PubMed Web of Science ®Google Scholar
• RAFII S: Circulating endothelial precursors: mystery, reality, and promise. j Gin. Invest. (2000) 105:17–19.
   PubMed Web of Science ®Google Scholar
• REYES M, DUDEK A, JAHAGIRDAR B, KOODIE L, MARKER PH,VERFAILLIE CM: Origin of endothelial progenitors in human postnatal bone marrow. I Clin. Invest. (2002) 109:337–346.
   PubMed Web of Science ®Google Scholar
• RAFII S, LYDEN D: Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. (2003) 9:702–712.
   PubMed Web of Science ®Google Scholar
• LIN Y, WEISDORF DJ, SOLOVEY A, HEBBEL RP: Origins of circulating endothelial cells and endothelial outgrowth from blood. I Clin. Invest. (2000) 105:71–77.
   PubMed Web of Science ®Google Scholar
• LYDEN D, HATTORI K, DIAS S et al.:Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. (2001) 7:1194–1201.
   PubMed Web of Science ®Google Scholar
• DAVIDOFF AM, NG CY, BROWN P et al.: Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Gin. Cancer Res. (2001) 7:2870–2879.
   Web of Science ®Google Scholar
• ••Important study demonstrating that bonemarrow-derived endothelial cell precursors can be used as vehicles to deliver therapeutic genes to tumour vasculature.
   Google Scholar
• DE PALMA M, VENNERI MA, ROCA C, NALDINI L: Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. (2003) 9:789–795.
   PubMed Web of Science ®Google Scholar